Na Thi Nguyen
Overview
Explore the profile of Na Thi Nguyen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yabuki Y, Mitsuhashi A, Ogino H, Yoshida A, Nguyen N, Yoneda H, et al.
Int J Cancer
. 2024 Dec;
156(9):1814-1825.
PMID: 39686841
Immune checkpoint inhibitors (ICIs) targeting programmed death ligand-1 (PD-L1) provide clinical benefits for various advanced malignancies. However, the predictive factors that determine sensitivity to ICIs have not been fully elucidated....
2.
Yoneda H, Mitsuhashi A, Yoshida A, Ogino H, Itakura S, Nguyen N, et al.
Cancer Sci
. 2023 Dec;
115(2):357-368.
PMID: 38148492
Combination immunotherapy with multiple immune checkpoint inhibitors (ICIs) has been approved for various types of malignancies, including malignant pleural mesothelioma (MPM). Podoplanin (PDPN), a transmembrane sialomucin-like glycoprotein, has been investigated...
3.
Kozai H, Ogino H, Mitsuhashi A, Nguyen N, Tsukazaki Y, Yabuki Y, et al.
Thorac Cancer
. 2023 Dec;
15(5):369-378.
PMID: 38146645
Background: Immune checkpoint inhibitors (ICIs) are a revolutionary paradigm in the treatment of thoracic malignancies and chemoimmunotherapy is a current standard care in this field. Chemotherapeutic agents are known to...
4.
Mitsuhashi A, Koyama K, Ogino H, Afroj T, Nguyen N, Yoneda H, et al.
Cell Rep
. 2023 Mar;
42(3):112162.
PMID: 36870329
Recent clinical trials revealed that immune checkpoint inhibitors and antiangiogenic reagent combination therapy improved the prognosis of various cancers. We investigated the roles of fibrocytes, collagen-producing monocyte-derived cells, in combination...
5.
Mitsuhashi A, Kondoh K, Horikawa K, Koyama K, Nguyen N, Afroj T, et al.
Cancer Sci
. 2021 Oct;
112(12):4853-4866.
PMID: 34628702
Immune checkpoint inhibitor (ICI) programmed death (PD)-1/PD-ligand 1 (PD-L1) blockade has been approved for various cancers. However, the underlying antitumor mechanisms mediated by ICIs and the predictive biomarkers remain unclear....
6.
Afroj T, Mitsuhashi A, Ogino H, Saijo A, Otsuka K, Yoneda H, et al.
J Immunol
. 2021 Jan;
206(6):1204-1214.
PMID: 33504617
Fibrocytes, a distinct population of collagen-producing, monocyte-derived cells, are involved in wound healing as well as fibrotic diseases. Recently, fibrocytes have been revealed to play a role in the tumor...